People with type 2 diabetes who use semaglutide drugs like Ozempic and Wegovy appear to have a lower risk of Alzheimer's ...

Compared to other diabetes medications, semaglutide might offer added protection against Alzheimer’s for type 2 diabetes ...

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing ...

The active ingredient in Ozempic and Wegovy has once again proven to have health effects outside of weight loss in a huge ...

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA ...